ArticleJournal of cellular biochemistry2019
The role of resveratrol in bone marrow-derived mesenchymal stem cells from patients with osteoporosis.
Article in Journal of cellular biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Effects of Resveratrol, Curcumin and Quercetin Supplementation on Bone Metabolism-A Systematic Review.Nutrients · 2022Pooled it
- Reactivation ofInternational journal of molecular sciences · 2026Article
- Evaluation of the effect of resveratrol on bone healing after tooth extraction in rats treated with zoledronic acid.Scientific reports · 2025Article
- Bidirectional regulation factor of bone marrow mesenchymal stromal cells differentiation: a focus on bone-fat balance in osteoporosis.Stem cell research & therapy · 2025Review
- Plant-derived food bioactives in bone health: from multi-targeted roles to molecular mechanisms in osteoporosis.Frontiers in nutrition · 2025Review
- A Review on Synthetic PLGA Polymer Incorporated with Phytocompounds: Elucidating the Molecular Cascades for Osteoporosis Treatment.Current pharmaceutical design · 2025Review
- The Role of Mitochondrial Homeostasis in Mesenchymal Stem Cell Therapy-Potential Implications in the Treatment of Osteogenesis Imperfecta.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Regulation Mechanisms and Maintenance Strategies of Stemness in Mesenchymal Stem Cells.Stem cell reviews and reports · 2024Review
- Activating Wnt/β-catenin signaling by autophagic degradation of APC contributes to the osteoblast differentiation effect of soy isoflavone on osteoporotic mesenchymal stem cells.Acta pharmacologica Sinica · 2023Article
- Review
- METTL3-mediated long non-coding RNA MIR99AHG methylation targets miR-4660 to promote bone marrow mesenchymal stem cell osteogenic differentiation.Cell cycle (Georgetown, Tex.) · 2023Article
- Activation of Functional Somatic Stem Cells Promotes Endogenous Tissue Regeneration.Journal of dental research · 2022Article
- Astragaloside IV protects against iron loading-induced abnormal differentiation of bone marrow mesenchymal stem cells (BMSCs).FEBS open bio · 2021Article
- Resveratrol can enhance osteogenic differentiation and mitochondrial biogenesis from human periosteum-derived mesenchymal stem cells.Journal of orthopaedic surgery and research · 2020Article
- Anti-aging Effects of Calorie Restriction (CR) and CR Mimetics based on the Senoinflammation Concept.Nutrients · 2020Review
- Resveratrol suppresses lipopolysaccharide-mediated activation of osteoclast precursor RAW 264.7 cells by increasing miR-181a-5p expression.International journal of immunopathology and pharmacologyArticle
- Therapeutic Potential of Resveratrol in Cancer and Neurodegenerative Disorders: A Current Review.BioFactors (Oxford, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the effects of resveratrol on BMSCs from patients with osteoporosis. The cell viability and proliferation of BMSCs after treatment with different concentrations of resveratrol was respectively observed by MTT assay and EdU staining. The apoptosis was assessed using by TUNEL staining and the pluripotency was analyzed by quantitative reverse transcription-PCR (qRT-PCR). The osteogenic differentiation and adipogenic differentiation were determined by alkaline phosphatase (ALP) staining, alizarin red S (ARS) staining, oil red O (ORO) staining and qRT-PCR analysis. MTT assay showed that Res at 40, 80, 100 μM markedly improved the cell proliferation of BMSCs from patients with osteoporosis. EdU staining indicated that Res treatment significantly accelerated the proliferation of BMSCs. In addition, the results of TUNEL staining revealed that Res at 40, 80, 100 μM inhibited the osteoporosis-related apoptosis of BMSCs. qRT-PCR analysis explored that Res treatment played a positive role in the pluripotency in BMSCs. ALP, ARS staining and qRT-PCR demonstrated that Res promoted the differentiation of BMSCs into osteoblasts, especially at 80 μM. ORO staining and qRT-PCR analysis proved that treatment of Res inhibited the adipogenesis of BMSCs isolated from patients with osteoporosis. Our findings suggested that Res can play a vital role in the cell viability, proliferation, apoptosis, pluripotency, osteogenesis and adipogenesis of BMSCs. And Res might be an efficient therapeutic approach for treating patients with osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.